Category: Pharma & Biotech

Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100

SHARE THIS POST Treatment of pediatric ulcerative colitis will be pursued using targeted cannabinoid therapy that avoids drug psychoactivity LOS ANGELES, CA – ( January 17, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease. The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA’s Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions. Vitality Biopharma’s gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders. The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis. Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls. “In young children,...

Read More

Alliance Growers Update on 2017 Audited Financials

SHARE THIS POST January 17, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) reports that today the company will file its financial statements, management discussion and analysis, and certification of annual filings for the year ended August 31st, 2017 (collectively, the “2017 Financials”). The British Columbia Securities Commission has been contacted and it is expected that the cease trade order against the Company and securities will be lifted on Friday, January 19, 2018 to allow trading to resume on the Canadian Securities Exchange (“CSE”). The Company would also like to inform investors that our email “info@alliancegrowers.com” has been upgraded and we will now be able to respond to queries. Commenting on 2017 Financials, Dennis Petke, Alliance Growers President and CEO states “Alliance went through its growing pains in the last two years and is now going to the next level thanks to our recent successful financing and continued support of our loyal shareholders.  Going forward we now have an appropriate budget to meet our continuous disclosure obligations in a more timely manner.  We are very pleased to enter 2018 with many exciting projects that we will be able to execute upon with our current financing proceeds and with our next $5 million raise expected to be completed in the coming weeks.  Alliance Growers has many exciting prospects on...

Read More

Crown Baus Capital (OTC: CBCA) Acquires Military Grade CryptoGraphic Secure Online Communications System; Cannabis Science (OTC: CBIS) Measures Asset Backed Blockchain CryptoCurrency Usage with CryptoGraphic Systems Integration

SHARE THIS POST BEVERLY HILLS, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) — Crown Baus Capital, Inc., (CBCA) a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment & Media, Education, and Financial Services is pleased to announce it has acquired a military grade CryptoGraphic secure Online Communications System, Cannabis Science (CBIS) measures blockchain CryptoCurrency usage with asset backed, CryptoGraphic systems and general public multiple application usage. The CBIS Security Team (CBISST) will be integrating the CBCA CrytopGraphics system between the two companies adding a unique concept for security and privacy issues to the new and burgeoning blockchain CryptoCurrency industry. This marks the release of the first CryptoGraphic messenger mobile application of its kind. The secure message system introduces “Ghost Chat,” which is a new way to privately communicate with friends, family, and business associates. When you walk into the grocery store and buy some groceries, you don’t need to fill out an application form and submit your ID to pay with cash: you just pay and go. This type of CryptoGraphic interface allows the same type of transaction, only difference is; it’s all done online. The Crown Baus CryptoGraphics systems offers many special and unique features to protect a user’s identity while communicating designed for sending data back and forth over the internet and other “secure” communications ports. For example, with the selection of a built-in countermeasures...

Read More

Abattis Enters Into Definitive Agreement to Acquire Green Tree Therapeutics

SHARE THIS POST JANUARY 11, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news releases dated December 22, 2017, it has entered into a definitive agreement (the “Definitive Agreement”) to acquire (the “Acquisition”) Green Tree Therapeutics Corporation (“GTT”, “Green Tree” or “GT Therapeutics Corporation”). GTT’s brands are currently sold in a wide variety of brick and mortar locations across North America, including wholesale channels. The Green Tree acquisition will bring Abattis 10 unique branded SKUs and a series of marketing, licensing, and technology rights. Upon closing of the Acquisition, products within the Green Tree brand will made available through Abattis’s wholly-owned subsidiary Vergence Naturals Ltd. (“Vergence”). “Abattis has always seen Green Tree as a perfect fit to merge with existing products within our marketing wing in Vergence,” stated Rob Abenante, President and CEO of Abattis. “Acquiring GTT will complement our retail offerings through Vergence and provide a solid entry point into the vaporizers market.” Moving forward within Abattis, Green Tree will continue to be engaged in expanding its product offerings for alternate cannabis products, including capsules, and lotions. “The key to this deal is our gained access to retail through integrating GTT’s products, including the Green Tree brand of vaporizers, which are renowned for their ability to deliver the therapeutic benefits of CBD and...

Read More

Scythian Biosciences Corp. Announces Upgrade to the OTCQB Marketplace

SHARE THIS POST TORONTO, Jan. 10, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSX-V:SCYB) (Frankfurt:9SB) (OTCQB:SCCYF) is pleased to announce that it has been upgraded to the OTCQB Marketplace as of January 10, 2018 and will be traded under the symbol “SCCYF”. “We look forward to broadening our shareholder base by completing a listing on the OTCQB Marketplace so that investors in the United States may more easily purchase and sell our securities on the aftermarket”, said Jonathan Gilbert, Chief Executive Officer. About Scythian Biosciences Corp. Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.  Scythian’s mission is to be the first accepted drug regimen for concussive treatment.  Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian’s scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s clinical studies to be undertaken at their world-class facilities.    Gillian A. Hotz, PhD, is leading Scythian’s program at the University of Miami. ...

Read More

Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

SHARE THIS POST Dr. Ascher Shmulewitz, Interim CEO, Discusses Strategy That Includes Additions to Drug Development TEL AVIV, Israel, Jan. 9, 2018 /PRNewswire/ — Therapix Biosciences Ltd. (NASDAQ: TRPX) (“Therapix” or the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is expanding into precision medicine through a new fully-owned subsidiary in order to develop novel solutions for pain. This new subsidiary will complement the Company’s cannabinoid-based drug development strategy. Ascher Shmulewitz, M.D., Ph.D., Interim CEO of Therapix, said, “We believe there is a large gap in medicine between current pharmaceutical treatments and the specific requirements of patients, which we plan to address. Recently, this gap has come into particular focus through the large and growing opioid crisis, which is having an extreme cost on human lives. The need for novel solutions has driven our decision to build a precision medicine arm while continuing to pursue our existing R&D efforts targeting the endocannabinoid system.” Therapix will elaborate on this additional strategic area of focus, with the goal of creating a full-circle, patient-centric approach during a corporate presentation today at 3:00 pm (PST) the Biotech Showcase™ 2018 in San Francisco, California. Therapix has previously announced a Memorandum of Understanding with Israel’s Assuta Medical Centers, Ltd., to develop first-in-class therapeutic products in the fields of precision medicine and cannabinoids. The Company has also announced a pre-clinical study...

Read More